Company profile

Ticker
APYX
Exchange
Employees
Incorporated in
Location
Fiscal year end
Former names
An Con Genetics Inc, Bovie Medical Corp, BOVIE MEDICAL Corp
SEC CIK
IRS number
112644611

APYX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 May 20
12 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 5M 8.38M 7.58M 6.65M
Net income -1.95M -5.81M -4.31M -4.34M
Diluted EPS -0.17 -0.13 -0.13
Net profit margin -39.04% -69.27% -56.91% -65.24%
Operating income -7.49M -5.93M -4.7M -4.47M
Net change in cash 49.14M 937K -2.2M -302K
Cash on hand 51.38M 2.24M 1.3M 3.5M
Cost of revenue 2.01M 2.82M 2.28M 1.98M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 28.24M 16.69M 10.23M 8.82M
Net income -19.71M 62.72M -5.06M -11.55M
Diluted EPS -0.58 1.83 -0.17 -0.15
Net profit margin -69.79% 376% -49.46% -131%
Operating income -20.87M -14.28M -13.89M -11.39M
Net change in cash -4.23M -3.48M -4.51M 2.65M
Cash on hand 2.24M 6.47M 9.95M 14.46M
Cost of revenue 9.14M 5.78M 3.28M 3.7M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
13 May 20 Goodwin Charles D. II Common Stock Buy Aquire P No 3.299 28,250 93.2K 28,250
15 Jan 20 Todd Hornsby Stock Option (Option to Buy) Common Stock Grant Aquire A No 8.18 100,000 818K 100,000
15 Jan 20 Goodwin Charles D. II Stock Option (Option to Buy) Common Stock Grant Aquire A No 8.18 243,000 1.99M 243,000
15 Jan 20 Tara Semb Stock Option (Option to Buy) Common Stock Grant Aquire A No 8.18 96,000 785.28K 96,000
15 Jan 20 Moshe Citronowicz Stock Option (Option to Buy) Common Stock Grant Aquire A No 8.18 72,000 588.96K 72,000
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
Proequities 0 0

Financial report summary

?
Competition
MedtronicConmedMedtronic
Risks
  • The energy-based medical device industry in the aesthetics market is highly competitive and we may be unable to compete effectively.
  • Maintaining strong relationships with plastic surgeons, cosmetic physicians, and other healthcare professionals, is critical to the success of our product commercialization strategy.
  • We rely on our internal sales force and sales partners to market and sell our products. If we are unable to hire, effectively train, and retain these professionals, future sales and profitability may be adversely affected.
  • If we are unable to successfully introduce new products or fail to keep pace with competitive advances in technology, our business, financial condition and results of operations could be adversely affected. In addition, our research and development efforts rely upon investments and alliances and we cannot guarantee that any previous or future investments or alliances will be successful.
  • Even if we are successful in developing new, or enhancing our existing products, there are various circumstances that could prevent their successful commercialization.
  • Our industry is highly regulated by the U.S. Food and Drug Administration and international regulatory authorities, as well as other governmental, state and federal agencies which have substantial authority to establish criteria which must be complied with in order for us to continue in operation.
  • Changes in U.S. trade policies could significantly increase the cost of imported goods into the United States, which may materially reduce our sales or profitability.
  • Our operations may experience higher costs to produce our products as a result of changes in prices for oil, gasoline and other commodities.
  • The recent Coronavirus outbreak has been declared a pandemic by the World Health Organization and recently has spread to the United States and many other parts of the world and may continue to adversely affect our business operations, employee availability, financial condition, liquidity and cash flow for an extended period of time.
  • We rely on certain suppliers, subcontractors, and manufacturers for raw materials and other products and are vulnerable to fluctuations in the availability and price of such products and services.
  • If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
  • We have been and may in the future become subject to litigation proceedings that could materially and adversely affect our business.
  • Our business is subject to the potential for recalls or safety alerts, litigation and negative publicity associated with defects or failures of our products, or their misuse\off-label use by physicians.
  • Economic conditions could adversely affect our business and financial condition.
  • There may be circumstances that arise that may cause us to use some of our existing financial assets ineffectively.
  • We may, in the future, identify deficiencies in controls over financial reporting.
  • We are at risk of being the victim of a cyber-attack or a security breach that may expose confidential customer, product and Company data or compromise our internal IT infrastructure. This could lead to liabilities resulting from failure to comply with US and foreign data security and privacy regulations and negative impacts to our business operations.
  • Our manufacturing facilities are located in Clearwater, Florida and Sophia, Bulgaria and could be affected due to multiple weather risks, including risks to our Florida facility from hurricanes and similar phenomena.
  • The market price of our stock has been and may continue to be highly volatile.
  • We have no present intention to pay dividends on our common stock and, even if we change that policy, we may be unable to pay dividends on our common stock.
  • Exercise of options issued by us will dilute the ownership interest of existing stockholders.
Management Discussion
  • Total revenue decreased by 11.2% or approximately $0.6 million for the three months ended March 31, 2020 when compared with the three months ended March 31, 2019. Advanced Energy segment sales decreased 8.8% or approximately $0.4 million for the three months ended March 31, 2020 when compared with the three months ended March 31, 2019. The coronavirus pandemic resulted in decreased demand for our products, both domestically and internationally, in the first quarter of 2020 as many of our customers' businesses have been ordered to close, while numerous others have closed voluntarily. We expect that the decreased demand will continue into the second quarter of 2020 and possibly beyond.
  • Gross profit for the three months ended March 31, 2020, decreased by 16.3% year-over-year, to $3.0 million, compared to $3.6 million in the prior year. Gross margin for the three months ended March 31, 2020, was 59.7%, compared to 63.3% for the same period in 2019. The primary drivers of the change in gross profit margin were product mix within both our Advanced Energy and OEM segments, revenue mix between our segments, geographical revenue mix, and improved product margins in our Advanced Energy segment as a result of our continued manufacturing efficiency initiatives.
  • Our spending in the first quarter of 2020 reflected normal business activities into February and March and then a curtailment of certain costs associated with the impact of the COVID-19 pandemic, including restrictions on travel. While certain spending will decrease in the second quarter of 2020 as a result of a reduction in revenue and activities limited by the COVID-19 pandemic, much of our spending will continue. For example, while we have restricted new hirings, we have no plans to reduce our headcount or furlough any employees at this time. Certain costs will decline as the underlying activities are restricted by the COVID-19 pandemic, including travel and related expenses, clinical trials and physician training.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: achieve, advantage, American, back, BDO, began, behavior, Black, bringing, Bulgarian, burdensome, cancel, carryback, carryforward, China, Chinese, Codification, contractual, couple, created, Credit, curtail, curtailed, curtailment, data, decline, deep, deeper, deferral, denial, denying, depend, desired, discretionary, disposable, disregarded, disruption, distancing, earlier, economy, efficiency, elevating, eliminating, epidemic, European, evidence, expeditiously, experienced, experiencing, expose, exposure, failure, fascial, footnote, foreseeable, forfeiture, frame, freight, fulfilling, furlough, global, government, governmental, health, heat, Hedging, hiring, hospital, IDE, imposing, improbable, incomplete, innovative, internationally, issuance, joint, JPlasma, largely, Latin, lifted, limit, limited, LLP, loosen, mitigate, multiple, newly, NOL, North, notice, outbreak, oversight, pandemic, passion, payroll, people, personal, pertain, plastic, predict, predicted, preemptive, program, Protecting, protective, rapidly, receipt, recovery, recruit, redirect, reduction, refund, remit, remotely, responded, resurgence, Safety, scale, scope, shut, site, slowdown, Smaller, social, sooner, source, split, spread, strain, strong, subside, supplier, taxable, temporarily, trade, transformative, trauma, travel, undergo, underlying, unintended, unique, unpredictable, USA, validating, variance, vendor, venture, verifying, virtually, volatility, volume, world, yield
Removed: ablation, advisory, agreed, amounted, announced, apply, approach, ascertain, August, beam, Bovie, brand, classification, classified, clearance, coagulation, collected, commercialization, commercializing, comparative, compare, complement, connection, consisting, consulting, continuing, cutting, Deeter, developed, developer, discontinued, discounted, divested, divestiture, drove, Electro, electrosurgical, emphasize, entered, equal, equity, establish, examination, expand, fail, financing, FL, flow, forecast, formal, Frazier, function, functioning, generator, hierarchy, iii, impaired, implemented, inherently, initial, instrument, Instrumentation, intellectual, internally, ionization, irrevocable, lease, leasing, Licensing, liquid, LLC, manner, manufacture, Marketable, minimal, modestly, modified, monitoring, mortgage, negatively, netted, objective, office, Patent, patented, plan, play, price, priority, produce, proprietary, pursuant, quoted, raw, reclassification, reclassified, recoverable, regulatory, remain, render, repayment, role, Service, shared, short, Sofia, soft, Specialty, specification, stable, strategic, supported, Symmetry, team, technique, Tennessee, transition, ultimately, undiscounted, unrealized, withdrew